GlobalData on MSN6d
Pfizer and AstraZeneca debate: when “the greater good” mattersWhen “the Greater Good” Matters The business pages, and now the mainstream media, have been dominated over the last week with news of Pfizer’s proposed $106bn takeover of AstraZeneca, which would make ...
AstraZeneca is continuing to study AZD8205 as a monotherapy in dose optimization expansion cohorts of patients with ...
Zacks.com on MSN9h
AZN Stock Slips as Dato-DXd Cancer Study Misses Survival GoalAstraZeneca AZN and Japanese partner Daiichi Sankyo announced that their antibody-drug conjugate, datopotamab deruxtecan ...
The NHS is offering autumn Covid boosters to the most vulnerable in October. Many pharmacies also now sell the Covid jab ...
HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC ...
An AstraZeneca immunotherapy improved survival rates in patients with bladder cancer, results that could reshape treatment of ...
Adult Vaccine Market Adult Vaccine Market Dublin, Sept. 10, 2024 (GLOBE NEWSWIRE) -- The "Adult Vaccine Market Report, ...
Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...
More than 75% of the cohort started a TNF inhibitor during the selected time frame. For the rest, JAK inhibitors were the ...
The greatest disparity in BC-specific survival was observed in women with HR+ HER2− tumors, with Black women having a 50% ...
AstraZeneca on Wednesday convinced a federal judge in Delaware to throw out a jury's decision that the company owes $107.5 ...
Patients with HER2-positive advanced or metastatic breast cancer received trastuzumab deruxtecan every 3 weeks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback